# US 2014/0154298 A1 · Liposomes useful for drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154298 A1
- Document ID: US20140154298A1
- Status: Published application
- Kind: A1
- Application number: 14/175,365
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2005-05-02
- Assignees: Merrimack Pharmaceuticals, Inc.
- Applicants: Merrimack Pharmaceuticals, Inc.
- Inventors: Keelung HONG; Daryl C. Drummond; Dmitri Kirpotin
- Web page: https://patentgrep.com/patent/US20140154298A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/10: for impotence
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/245: Escherichia (G)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07H 13/12: by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S 977/906: Drug delivery
- Y10S 977/907: Liposome
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.

## Claims

### Claim 1

A liposomal composition comprising liposomes in an aqueous medium, the liposomes having an interior aqueous space separated from the aqueous medium by a membrane comprising an uncharged lipid component and a neutral phospholipid, with, entrapped inside the liposomes: 1) a cationic pharmaceutical entity and sucrose octasulfate, or 2) a cationic pharmaceutical entity and sucrose octasulfate and a substituted ammonium compound; wherein, the pharmaceutical entity entrapped inside the liposomes is at a concentration that exceeds the concentration of the pharmaceutical entity in the aqueous medium.

### Claim 2 (depends on 1)

The liposomal composition of claim 1, wherein the substituted ammonium compound has a formula: R1—(R2—)N+(—R3)—R4, wherein N is a an ammonium nitrogen atom, each of R1, R2, R3, and R4 is independently a hydrogen atom or an organic group having each independently not more than 8 carbon atoms, and in totality not more than 18 carbon atoms inclusive, wherein at least one of R1, R2, R3, and R4 is an organic group; wherein the organic group is independently alkyl, alkylidene, heterocyclic alkyl, cycloalkyl, aryl, alkenyl, cycloalkenyl, or a hydroxy-substituted derivative thereof, optionally including S, O, or N atoms forming an ether, ester, thioether, amine, or amide bond; and wherein at least three of R1, R2, R3, and R4 are the organic groups; or at least one of the organic groups has a secondary or tertiary carbon atom directly linked to the ammonium nitrogen atom.

### Claim 3 (depends on 1)

The liposomal composition of claim 1, wherein the substituted ammonium compound is selected from the group consisting of isopropylethylammonium, isopropylmethylammonium, diisopropylammonium, tert-butylethylammonium, dicyclo-hexylammonium, morpholinium, pyridinium, piperidinium, pyrrolidinium, piperazinium, tert-butylammonium, 2-ammonio-2-methyl-propanol-1,2-ammonio-2-methyl-propandiol-1,3, tris-(hydroxyethyl)-ammoniomethane, N,N′-diethyl-ethanolammonium, N,N′,N″-tris-(2-hydroxyethyl)ammonium, N,N′-bis-(2-hydroxyethyl)ethylammonium, trimethyl-ammonium, triethylammonium, diethylmethyl-ammonium, diisopropylethylammonium, triisopropylammonium, N-methyl-morpholinium, 1-(2-hydroxyethyl)piperidinium, 1-methylpyrrolidinium, 1,4-dimethyl-piperazinium, tetramethylammonium, tetraethyl-ammonium, and tetrabutylammonium.

### Claim 4 (depends on 1)

The liposomal composition of claim 1, wherein the substituted ammonium compound is triethylammonium.

### Claim 5 (depends on 1)

The liposomal composition of claim 1, wherein the substituted ammonium compound is diethylammonium.

### Claim 6 (depends on 1)

The liposomal composition of claim 1, wherein the membrane further comprises a polymer-conjugated lipid.

### Claim 7 (depends on 6)

The liposomal composition of claim 6, wherein the polymer-conjugated lipid is a polyethylene glycol-conjugated lipid.

### Claim 8 (depends on 7)

The liposomal composition of claim 7, wherein the polyethylene glycol-conjugated lipid is N-(methoxy-poly(ethylene glycol)-oxycarbonyl)-distearoylphosphatidylethanolamine (PEG-DSPE).

### Claim 9 (depends on 1)

The liposomal composition of claim 1, wherein the composition is a fluid pharmaceutical formulation for parenteral administration.

### Claim 10 (depends on 1)

The liposomal composition of claim 1, wherein molar ratio of the pharmaceutical entity to the totality of the lipids is at least 1.0.

### Claim 11 (depends on 1)

The liposomal composition of claim 1, wherein the relative amounts of the pharmaceutical entity and the sucrose octasulfate are near the point of stoichiometric equivalency.

### Claim 12 (depends on 1)

The liposomal composition of claim 1, wherein the relative amounts of the pharmaceutical entity and the sucrose octasulfate are at the point of stoichiometric equivalency.

### Claim 13 (depends on 1)

The liposomal composition of claim 1, wherein the pharmaceutical entity and the sucrose octasulfate are comprised in the form of a salt.

### Claim 14 (depends on 1)

The liposomal composition of claim 1, wherein the neutral phospholipid comprises a diacylphosphatidylcholine.

### Claim 15 (depends on 14)

The liposomal composition of claim 14, wherein the diacylphosphatidylcholine is 1,2-distearoyl-sn-phosphatidylcholine (DSPC).

### Claim 16 (depends on 1)

The liposomal composition of claim 1, wherein the aqueous medium comprises HEPES and NaCl.

### Claim 17 (depends on 1)

The liposomal composition of claim 1, wherein the pharmaceutical entity has been partially or substantially removed from the aqueous medium.

### Claim 18 (depends on 1)

The liposomal composition of claim 1, wherein the pharmaceutical entity is selected from the group consisting of an antihistamine, an anti-protozoal, an anti-schistosomal, and antifungal, an antimicrobial, an antimycobacterial, an antiviral, a cholinergic quaternary ammonium compound, an anti-Alzheimer aminoacridine, an anti-Parkinsonal, an anti-muscarinic, an adrenergic, an ergotamine derivative, a central action myorelaxant, a beta-adrenoblocker, a benzodiazepine, an antiarrhythmic, a local anesthetic, an ACE inhibitor, an antilipidemic, an HMG-coA inhibitor, a hypotensive, and a non-coronary vasodilator.

### Claim 19 (depends on 18)

The liposomal composition of claim 18, wherein the pharmaceutical entity is an antimicrobial.

### Claim 20 (depends on 18)

The liposomal composition of claim 18, wherein the pharmaceutical entity is an anti-protozoal.

### Claim 21

A pharmaceutical composition, the composition comprising a liposome in an aqueous medium, wherein the liposome comprises an interior space that: 1) is aqueous, 2) is separated from the aqueous medium by a membrane comprised of one or more lipids, and 3) contains sucrose octasulfate polyanion and a cationic antimicrobial or antiprotozoal agent.

### Claim 22 (depends on 21)

The composition of claim 21 wherein molar ratio of the agent to the one or more lipids in totality is at least about 0.05, at least about 0.1, at least about 0.2, at least about 0.3, at least about 0.5, at least about 0.7, or at least about 1.0.

### Claim 24 (depends on 22)

The composition of claim 22 wherein the lipids comprise a neutral PEG-lipid derivative or an anionic PEG-lipid derivative.

### Claim 25 (depends on 21)

The composition of claim 21 wherein the in the sucrose octasulfate polyanion and the cationic antimicrobial or antiprotozoal agent are comprised in the form of a salt.

### Claim 26 (depends on 21)

The composition of claim 21 wherein the composition is a fluid formulation for parenteral administration.
